Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) forthe lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).
|19 Jan 2022||$1.62||$-0.11||-6.40%||723,579||$1.72||$1.72||$1.61|
|18 Jan 2022||$1.72||$0.00||0.00%||211,943||$1.71||$1.74||$1.69|
|17 Jan 2022||$1.72||$0.00||0.00%||210,498||$1.73||$1.75||$1.67|
|14 Jan 2022||$1.72||$-0.07||-3.93%||807,779||$1.77||$1.78||$1.66|
|13 Jan 2022||$1.78||$-0.01||-0.56%||405,290||$1.84||$1.85||$1.76|
|12 Jan 2022||$1.79||$0.04||2.28%||237,172||$1.77||$1.81||$1.75|
|11 Jan 2022||$1.76||$-0.04||-2.23%||402,091||$1.80||$1.80||$1.74|
|10 Jan 2022||$1.80||$-0.03||-1.65%||238,393||$1.82||$1.83||$1.79|
|07 Jan 2022||$1.82||$0.00||0.00%||504,569||$1.84||$1.85||$1.79|
|06 Jan 2022||$1.83||$-0.08||-4.20%||376,914||$1.93||$1.93||$1.83|
|05 Jan 2022||$1.91||$0.01||0.53%||343,441||$1.94||$1.94||$1.87|
|04 Jan 2022||$1.90||$0.01||0.53%||196,036||$1.88||$1.93||$1.88|
|31 Dec 2021||$1.89||$-0.01||-0.53%||250,112||$1.89||$1.92||$1.88|
|30 Dec 2021||$1.90||$-0.02||-1.04%||75,874||$1.93||$1.93||$1.89|
|29 Dec 2021||$1.92||$-0.03||-1.54%||136,387||$1.94||$1.95||$1.91|
|24 Dec 2021||$1.95||$0.03||1.56%||88,623||$1.93||$1.98||$1.92|
|23 Dec 2021||$1.92||$-0.03||-1.54%||85,225||$1.94||$1.95||$1.90|
|22 Dec 2021||$1.95||$0.06||3.17%||200,899||$1.89||$1.95||$1.88|
|21 Dec 2021||$1.89||$0.08||4.42%||278,147||$1.82||$1.92||$1.80|
|Ms Helen E Fisher||Non-Executive Director||Feb 2021||
Ms Fisher is Chief Executive Officer and managing director of Bio Capital Impact Fund (BCIF) and Non-Executive Director (NED) and Chair of the Audit and Risk Management Committee of Calix Limited (ASX: CXL), a company with a platform technology with applications in climate change, water management, biotech, and pharmaceutical areas. Prior to establishing BCIF, she was a partner of Deloitte and led Deloitte's life science practice in Australia for 5 years, having had many years' experience in the life sciences and health care sector.
|Mr Paul Rennie||Chief Executive OfficerManaging DirectorInterim Chairman||May 2014||
Mr Rennie has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. His experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as National Sales and Marketing Manager and Soltec (FH Faulding Ltd) as their Director of business development. He also led the commercialisation of Recaldent a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently he worked in a number of positions with Mesoblast Ltd. He was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. For the past 4 years, he has worked full time at Paradigm Biopharmaceuticals Limited
|Mr Amos Meltzer||Non-Executive Director||Dec 2020||
Mr Meltzer is a scientist and an intellectual property lawyer with over 25 years of experience in international trade and in commercialising technologies principally in the life sciences sector. He has presided over life science research and product development projects clinical trials as well as the commercialisation of life sciences assets through both licensing and the sale and marketing of a pharmaceutical product. Previously, he has served as in house counsel and IP director at two Nasdaqlisted companies Compugen and Gilat, as a non-executive director of a biotechnology company Evogene and as VP of Business Development and then CEO of an ASX-listed biopharmaceutical company Immuron. He currently serves as Chief Operating Officer of neuro-medical device company Synchron, chairman of the board of surgeons' education services company Vasculab and as a legal advisor to a number of ASX listed and private life science companies.
|Mr John Gaffney||Non-Executive Director||Sep 2014||
Mr Gaffney LL.M is a lawyer with over 30 years' experience and has undertaken the AICD Company Directors qualification. He brings to the Board a compliance and corporate governance background and is experienced in financial services compliance. He also has corporate and commercial experience having worked with a major national law firm as a senior lawyer and also practised as a barrister at the Victorian Bar. Previously Mr Gaffney has been a Non-Executive Director of a US based biotechnology company and SelfWealth Ltd.
|Dr Donna Skerrett||Executive Director||Jul 2020||
Dr Skerrett, has more than 30 years' experience in transfusion medicine, cellular therapy, and transplantation. She brings a wealth of experience in medical, clinical, and regulatory affairs. Donna served previously as Chief Medical Officer at Mesoblast. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York, and prior to that was Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University's New York-Presbyterian Hospital. She has previously chaired the New York State Council on Blood and Transfusion Services, and served on the Board of Directors of the Fox Chase Cancer Center in Philadelphia
|Mr Kevin G Hollingsworth||Company Secretary||
|Kevin G Hollingsworth||Company Secretary||
|HSBC Custody Nominees (Australia) Limited||20,484,777||8.92%|
|Kzee Pty Ltd <Kzee Superannuation Fund A/C>||10,781,467||4.70%|
|Paul John Rennie||8,230,400||3.58%|
|Cs Third Nominees Pty Limited <HSBC Cust Nom Au Ltd 13 A/C>||4,349,240||1.89%|
|Nancy Edith Wilson-Ghosh <Ghosh Family A/C>||3,860,835||1.68%|
|Citicorp Nominees Pty Limited||3,852,323||1.68%|
|BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||3,594,952||1.57%|
|J P Morgan Nominees Australia Pty Limited||3,571,937||1.56%|
|Mr Evan Philip Clucas + Ms Leanne Jane Weston <Kuranga Nursery Super A/C>||2,627,913||1.14%|
|V Redford Pty Ltd <Redford S/F A/C>||2,423,500||1.06%|
|Mr Brett Langan||2,303,432||1.00%|
|Mjgd Nominees Pty Ltd <Bsmi A/C>||1,983,849||0.86%|
|BNP Paribas Noms Pty Ltd <Drp>||1,871,447||0.82%|
|Jgm Investment Group Pty Ltd <Muchnicki Family A/C>||1,737,408||0.76%|
|Ms Lenna Yu Ling Tye||1,521,631||0.66%|
|Australian Executor Trustees Limited <No 1 Account>||1,512,100||0.66%|
|BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C>||1,285,072||0.56%|
|Ten Luxton Pty Ltd <Abotomey S/F A/C>||1,200,000||0.52%|
|View 26 Pty Ltd <View 26 A/C>||1,150,050||0.50%|
|Hot Springs Superannuation Pty Limited <Hot Springs P/L S/F A/C>||1,132,910||0.49%|